GlassScriptPhysician profile
Joseph A Altamirando
NPI 1730498916
$2,291.91
in general payments reported to CMS, 2019-2025
29 companies · $97.45 in 2025
The $97.45 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $753 · 2022: $372 · 2023: $657 · 2024: $412 · 2025: $97.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $600.98 | 2021-2024 | Prolaris |
| Clarus Therapeutics INC. | $173.39 | 2021 | |
| Urovant Sciences INC | $170.21 | 2021-2022 | |
| Teleflex LLC | $147.54 | 2021 | |
| Clinical Laserthermia Systems Americas INC. | $135.28 | 2024 | Mobile Laser Unit |
| Antares Pharma, INC. | $118.03 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Telix Pharmaceuticals | $107.50 | 2024 | Illuccix |
| Medtronic, INC. | $104.78 | 2021 | |
| Ascensia Diabetes Care US INC. | $97.45 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $72.16 | 2023 | Bard Urinary Drainage Bag |
| Astellas Pharma US INC | $54.11 | 2021-2022 | |
| Blue Earth Diagnostics | $47.40 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $43.52 | 2021 | |
| Verity Pharmaceuticals INC. | $38.52 | 2022 | |
| Urogen Pharma, INC. | $37.75 | 2022-2023 | Jelmyto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $36.61 | 2021 | |
| Sumitomo Pharma America, INC. | $36.35 | 2023-2024 | Gemtesa |
| Ferring Pharmaceuticals INC. | $32.78 | 2024 | Adstiladrin |
| Rochester Medical Corporation | $30.04 | 2021 | |
| Janssen Biotech, INC. | $29.32 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.14 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $23.53 | 2022 | |
| Olympus America INC. | $22.93 | 2024 | Itind System |
| Halozyme INC | $21.05 | 2023 | |
| Tolmar, INC. | $19.36 | 2023 | |
| 180 Medical, INC. | $17.93 | 2021 | |
| Hollister Incorporated | $17.27 | 2023 | Infyna Chic, Onli |
| Amgen INC. | $14.71 | 2021 | |
| Acerus Pharmaceuticals Corporation | $13.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Altamirando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.